Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
EXTON, Pa., May 03, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent operational highlights on Thursday, May 10, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 3897293 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484-713-6133
[email protected]
